Swedbank AB acquired a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) in the fourth quarter, Holdings Channel reports. The fund acquired 90,900 shares of the company’s stock, valued at approximately $3,189,000.
Other hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its position in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the period. Navalign LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $46,000. NBC Securities Inc. acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $86,000. Mirae Asset Global Investments Co. Ltd. lifted its position in NewAmsterdam Pharma by 26.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after acquiring an additional 1,156 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at NewAmsterdam Pharma
In related news, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. This trade represents a 71.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Louis G. Lange sold 44,619 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the transaction, the director directly owned 10,360 shares of the company’s stock, valued at $315,151.20. The trade was a 81.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 881,512 shares of company stock valued at $28,350,236. Company insiders own 12.74% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
NASDAQ NAMS opened at $36.56 on Thursday. NewAmsterdam Pharma Company N.V. has a 1-year low of $16.78 and a 1-year high of $42.21. The company has a market capitalization of $4.27 billion, a P/E ratio of -20.42 and a beta of 0.02. The business has a 50 day moving average price of $33.16 and a 200 day moving average price of $34.21.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million during the quarter. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Stories
- Five stocks we like better than NewAmsterdam Pharma
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report).
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
